Overview

Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder

Status:
Terminated
Trial end date:
2017-12-15
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well giving docetaxel and lapatinib ditosylate together as second-line therapy works in treating patients with stage IV bladder cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving docetaxel and lapatinib ditosylate together may kill more tumor cells.
Phase:
Phase 2
Details
Lead Sponsor:
University of Southern California
Collaborators:
GlaxoSmithKline
National Cancer Institute (NCI)
Treatments:
Docetaxel
Lapatinib